Trial Profile
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.